According to the OPPI, launching a new drug in India is delayed by up to four years, compared to markets like the US and the European Union. This affects the launch of innovative and significant products in India. The lobby represents pharma giants including Novartis, Roche, AstraZeneca, Sanofi and Merck. The group blames the delay on complex clinical trial regulations.
